Sakarin

Sakarin

heparin

Manufacturer:

Sakar Healthcare

Distributor:

Macropharma Corp
Concise Prescribing Info
Contents
Heparin Na
Indications/Uses
Prophylaxis & treatment of venous thrombosis & its extensions, pulmonary embolism & peripheral arterial embolism. Atrial fibrillation w/ embolization. Diagnosis & treatment of acute & chronic consumptive coagulopathies (disseminated intravascular coagulation). Prevention of clotting in arterial & cardiac surgery; cerebral thrombosis in evolving stroke. Adjunct treatment of coronary occlusion w/ acute MI. Anticoagulant in blood transfusions, extracorporeal circulation, dialysis procedures & in blood samples for laboratory practices.
Dosage/Direction for Use
Deep SC Initially 5,000 u followed by 10,000 u. Adult weighing 68 kg Deep SC initially, 5,000 u followed by 10,000 u. Intermittent IV inj Initially 10,000 u undiluted or in 50-100 mL isotonic NaCl inj or 5,000-10,000 u undiluted or in 50-100 mL isotonic NaCl inj every 4-6 hr or 8,000-10,000 u of conc soln every 8 hr or 15,000-20,000 u of conc soln every 12 hr. Surgery of the heart & blood vessels Initially not <150 u/kg. Frequently, 300 u/kg to last <60 min or 400 u/kg to last longer than 60 min. Low dose prophylaxis of post-op thromboembolism 5,000 u 2 hr before surgery followed by 5,000 u for every 8-12 hr for 7 days or until the patient if fully ambulatory. Childn IV inj 50 u/kg followed by 100 u/kg every 4 hr to clotting time.
Contraindications
Special Precautions
Not intended for IM use. Increased danger of haemorrhage in conditions eg, subacute bacterial endocarditis, arterial sclerosis, increased capillary permeability during major surgery especially involving brain, spinal cord or eye; haemophilia, thrombocytopenia & some vascular purpuras; ulcerative lesions & continuous tube drainage of the stomach or the small intestine; menstruation liver disease w/ impaired hemostasis. Monitor coagulation test results. Heparin resistance. Women >60 yr. Pregnancy & lactation.
Adverse Reactions
Haemorrhage, allergic reactions; delayed onset thrombocytopenia; skin necrosis at the inj site.
Drug Interactions
May produce severe, prolonged HTN w/ MAOIs or TCAs. May cause severe, persistent HTN or CVA w/ vasopressor or ergot-type oxytocics.
MIMS Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)
ATC Classification
B01AB01 - heparin ; Belongs to the class of heparin group. Used in the treatment of thrombosis.
Presentation/Packing
Form
Sakarin soln for inj 1000 IU/mL
Packing/Price
5 mL x 1's
Form
Sakarin soln for inj 5000 IU/mL
Packing/Price
5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in